Severe Euglycaemic Ketoacidosis with SGLT2 Inhibitor Use in the Perioperative Period

 
There have been recent reports of patients with type 2 diabetes who are taking sodium-glucose co-transporter-2 (SGLT2) inhibitors (“gliflozins”) developing euglycaemic diabetic ketoacidosis (euDKA) leading to severe acidemia requiring ICU/HDU admission during the perioperative period. Dr Roger Traill from the Royal Prince Alfred Hospital provides more background and recommendations for practice here.
Copyright © Australian and New Zealand College of Anaesthetists.